Stocks Health care NRIX
NASDAQ · Health careNurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc. brought in $36.8M of revenue over the twelve months to May 31, 2026, down 58.4% from a year earlier. It posted a net loss of $341.4M. In fiscal 2025 capital spending exceeded operating cash flow by $263.5M. At May 31, 2026 it held $67.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 9, 2026.
What Nurix Therapeutics, Inc. does
Nurix Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NRIX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $84M | -$264.5M | -$3.05 | -$263.5M |
| 2024 | $54.5M | -$193.6M | -$2.88 | -$181.9M |
| 2023 | $77M | -$143.9M | -$2.65 | -$89.8M |
| 2022 | $38.6M | -$180.4M | -$3.71 | -$172.1M |
| 2021 | $29.8M | -$117.2M | -$2.73 | -$90M |
| 2020 | $17.8M | -$43.2M | -$2.76 | -$4.6M |
Latest SEC filings
What Nurix Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 23, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- July 9, 2026Quarterly report 10-Q · period to May 31, 2026
- July 9, 2026
- June 11, 2026
Questions about NRIX
What does Nurix Therapeutics, Inc. do?
Nurix Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NRIX.
Is Nurix Therapeutics, Inc. profitable?
No. Over the twelve months to May 31, 2026 it reported a net loss of $341.4M on revenue of $36.8M.
How much revenue does Nurix Therapeutics, Inc. make?
Over the twelve months to May 31, 2026 Nurix Therapeutics, Inc. reported revenue of $36.8M. That is 58.4% less than a year earlier.
When did Nurix Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 9, 2026. It covers the period to May 31, 2026. Its newest filing of any kind is the passive stake (5% or more) from September 23, 2026.
Similar companies
Follow NRIX
Get an email when Nurix Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow NRIX: get an email when it filesWhere the numbers come from
Financial figures are the values Nurix Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.